Literature DB >> 23831839

Muscle wasting: the gut microbiota as a new therapeutic target?

Laure B Bindels1, Nathalie M Delzenne.   

Abstract

Muscle wasting is characterized by a loss of muscle mass and strength, and occurs in several pathological conditions such as cancer, chronic heart failure, chronic infection and malnutrition. Muscle wasting can be caused by inflammation and inappropriate nutritional status. Interestingly, gut microbiota has recently been proposed as an environmental factor involved, among others, in energy sparing from the diet, and in the regulation of host immunity and metabolism. This review presents evidence supporting the existence of a gut microbiota-muscle axis and discusses the potential role and therapeutic interest of gut microbiota in muscle wasting, specifically in the context of cancer and malnutrition. This review also proposes possible molecular mechanisms underlying the gut microbiota-muscle axis. This article is part of a Directed Issue entitled: Molecular basis of muscle wasting.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cachexia; Gut microbiota; Muscle wasting; Prebiotics; Probiotics; Undernutrition

Mesh:

Year:  2013        PMID: 23831839     DOI: 10.1016/j.biocel.2013.06.021

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  56 in total

1.  Protective Effects of Ghrelin on Fasting-Induced Muscle Atrophy in Aging Mice.

Authors:  Chia-Shan Wu; Qiong Wei; Hongying Wang; Da Mi Kim; Miriam Balderas; Guoyao Wu; John Lawler; Stephen Safe; Shaodong Guo; Sridevi Devaraj; Zheng Chen; Yuxiang Sun
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-03-09       Impact factor: 6.053

2.  Molecular characterization of skin microbiota between cancer cachexia patients and healthy volunteers.

Authors:  Wei Li; Lei Han; Pengbo Yu; Chaofeng Ma; Xiaokang Wu; John E Moore; Jiru Xu
Journal:  Microb Ecol       Date:  2014-01-09       Impact factor: 4.552

3.  Biological Aging and the Human Gut Microbiota.

Authors:  Vincent J Maffei; Sangkyu Kim; Eugene Blanchard; Meng Luo; S Michal Jazwinski; Christopher M Taylor; David A Welsh
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-10-12       Impact factor: 6.053

Review 4.  Gut Microbiota in Obesity and Undernutrition.

Authors:  Nicolien C de Clercq; Albert K Groen; Johannes A Romijn; Max Nieuwdorp
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

Review 5.  Role of interleukin-6 in cachexia: therapeutic implications.

Authors:  Aditi A Narsale; James A Carson
Journal:  Curr Opin Support Palliat Care       Date:  2014-12       Impact factor: 2.302

6.  New Approaches to Treating Cardiac Cachexia in the Older Patient.

Authors:  Gohar Azhar; Jeanne Y Wei
Journal:  Curr Cardiovasc Risk Rep       Date:  2013-12-01

Review 7.  Cancer cachexia: understanding the molecular basis.

Authors:  Josep M Argilés; Sílvia Busquets; Britta Stemmler; Francisco J López-Soriano
Journal:  Nat Rev Cancer       Date:  2014-10-09       Impact factor: 60.716

8.  Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis.

Authors:  W H Wilson Tang; Zeneng Wang; Yiying Fan; Bruce Levison; Jennie E Hazen; Lillian M Donahue; Yuping Wu; Stanley L Hazen
Journal:  J Am Coll Cardiol       Date:  2014-10-27       Impact factor: 24.094

9.  Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice.

Authors:  Eveliina Munukka; Anniina Rintala; Raine Toivonen; Matts Nylund; Baoru Yang; Anna Takanen; Arno Hänninen; Jaana Vuopio; Pentti Huovinen; Sirpa Jalkanen; Satu Pekkala
Journal:  ISME J       Date:  2017-04-04       Impact factor: 10.302

10.  Effects of synbiotic supplementation on energy and macronutrients homeostasis and muscle wasting of critical care patients: study protocol and a review of previous studies.

Authors:  Najmeh Seifi; Mohammad Safarian; Mohsen Nematy; Reza Rezvani; Majid Khadem-Rezaian; Alireza Sedaghat
Journal:  Trials       Date:  2020-02-24       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.